What FVC defines extensive SSc-ILD?

FVC 20% = extensive. FVC ≥70% with HRCT <20% = limited ILD. Extensive disease has higher mortality and progressive fibrosing phenotype.

Which SSc antibodies predict ILD?

Anti-topoisomerase I (Scl-70): high risk of ILD, diffuse SSc. Anti-Th/To: lcSSc with high ILD and PAH risk. Anti-U3-RNP, anti-U11/U12 RNP: also ILD-associated. Anti-centromere: low ILD risk but high PAH risk.

What is the treatment for SSc-ILD?

Mycophenolate mofetil is first-line for SSc-ILD (SLS II trial). Nintedanib (antifibrotic) is approved for progressive fibrosing SSc-ILD regardless of FVC. Tocilizumab may reduce FVC decline in early dcSSc-ILD.

SSc-ILD Baseline Staging and Risk Stratification

Stage and risk-stratify SSc-ILD (systemic sclerosis interstitial lung disease) using FVC% predicted, HRCT extent, and anti-Scl-70 status. Identifies limited vs extensive ILD and guides nintedanib or mycophenolate initiation.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How It Works

Each component has a specific meaning:

FVC% predicted — The fvc% predicted recorded for the scenario being assessed.
HRCT extent — The hrct extent recorded for the scenario being assessed.
Anti-Scl-70 status — The anti-scl-70 status recorded for the scenario being assessed.

Note: Interpret the ssc-ild risk result against the thresholds and context described above.

How to Use

Enter the FVC% predicted, HRCT extent, anti-Scl-70 status for the scenario you are assessing. Stage and risk-stratify SSc-ILD (systemic sclerosis interstitial lung disease) using FVC% predicted, HRCT extent, and anti-Scl-70 status. Identifies limited vs extensive ILD and guides nintedanib or mycophenolate initiation. Use the ssc-ild risk result to inform your calculation.

Related Calculators

mRSS SSc

Hyper-niche Medical